Transatlantic Healthtech Fund, a global first, unveiled by Meridan Health Ventures

Transatlantic Healthtech Fund, a global first, unveiled by Meridan Health Ventures

A new transatlantic healthtech fund, previously known as KHP Ventures and now named Meridian Health Ventures, has been announced, bringing together leading health systems, venture investors, institutional investors, and academic centres of excellence. This fund aims to supercharge the growth of promising innovations for direct benefits to the NHS's patients and workforce, as well as the wider UK economy.

The team behind Meridian Health Ventures comprises entrepreneurs, investors, operators, regulators, industry leaders, academics, and clinicians. The fund's goal is to provide global and domestic growth opportunities for healthtech innovators in the UK, bridging the funding gap between Series A and B stages and accelerating the scaling of UK healthtech startups.

Key partners in this transatlantic fund include North American investors and ecosystems, such as those in the US and Canada. These partnerships facilitate market access and validation of UK innovations at scale in North America. Venture capital firms with transatlantic reach, like Hadean Ventures and Northzone, are also actively investing in UK healthtech and life sciences startups.

The benefits of these transatlantic collaborations are manifold. They help bridge the UK Series A to B funding gap, providing critical growth capital and strategic support to scale ventures beyond the initial funding rounds. Moreover, UK healthtech companies gain opportunities to pilot and scale solutions in larger or complementary healthcare markets, such as employer-based US systems or Canadian provinces, which helps de-risk the technology and improves commercial success chances.

Engagement with international investors and healthcare systems provides insights into diverse regulatory and clinical environments, enhancing product-market fit and adoption success in both UK and overseas markets. Acceleration via platforms and accelerators, like Digital Health London, also improves the startups’ visibility and readiness for scaling.

Firms such as Tendable, a UK NHS-validated mobile platform, have successfully expanded into Canadian healthcare providers, demonstrating tangible impact in both care quality and operational efficiency beyond the UK. Companies like Actithera, with transatlantic investment backing, have progressed innovative therapeutic platforms toward broad clinical applications, showcasing the role of cross-border financing in advancing high-impact health technologies.

Transatlantic healthtech funds help sustain innovation pipelines by overcoming inherent UK ecosystem challenges related to NHS integration complexity, regulatory barriers, and investor risk aversion. Cedars-Sinai Medical Center sees the partnership with Meridian Health Ventures as deeply aligned with its mission to provide the best care possible to patients around the world.

The current portfolio of Meridian Health Ventures includes Doccla, deepc, Patchwork, Tympa Health, Apian, iFAST Diagnostics, PocDoc, Phare Health, 52 North, and MediShout. The fund will help healthtech superscalers to thrive domestically in the UK while fast-tracking their growth in the US. Apian, a Meridian Health Ventures portfolio company, has grown alongside partners like Meridian Health Ventures and Trusts like Guy’s and St Thomas’ NHS Foundation Trust.

The partners in the fund are committed to harnessing accelerations in new digital and biomedical advances to deliver better, faster, and fairer healthcare. Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital, University College London Hospitals, Cedars-Sinai Medical Center, and Hartford HealthCare are among the backers of the fund. Apian's CEO, Alex Trewby, has stated that the new transatlantic fund creates a win-win for patients, clinicians, and health tech founders like themselves.

1. Meridian Health Ventures, a new transatlantic healthtech fund, aims to boost innovations that benefit NHS patients and the UK economy.
2. The fund comprises a team of entrepreneurs, investors, operators, regulators, industry leaders, academics, and clinicians.
3. Their goal is to offer global and domestic growth opportunities for UK healthtech innovators.
4. Key partners include North American investors and ecosystems, such as those in the US and Canada, bridging the funding gap between Series A and B stages.
5. Hadean Ventures and Northzone, with transatlantic reach, are actively investing in UK healthtech and life sciences startups.
6. Transatlantic collaborations help bridge the UK Series A to B funding gap, providing critical growth capital and strategic support.
7. UK healthtech companies gain opportunities to pilot and scale solutions in larger healthcare markets, such as employer-based US systems or Canadian provinces.
8. Engagement with international investors and healthcare systems provides insights into diverse regulatory and clinical environments.
9. This enhances product-market fit and adoption success in both UK and overseas markets, such as the US and Canada.
10. Acceleration via platforms and accelerators like Digital Health London improves startups’ visibility and readiness for scaling.
11. Firms like Tendable have expanded into Canadian healthcare providers, demonstrating impact in both care quality and operational efficiency.
12. Companies like Actithera, with transatlantic investment backing, have progressed innovative therapeutic platforms.
13. Transatlantic healthtech funds help sustain innovation pipelines by overcoming inherent UK ecosystem challenges.
14. Cedars-Sinai Medical Center views the partnership with Meridian Health Ventures as aligned with its mission to provide global care.
15. The current portfolio of Meridian Health Ventures includes companies like Doccla, deepc, Patchwork, Tympa Health, Apian, and more.
16. The fund aims to help healthtech superscalers to thrive domestically in the UK while fast-tracking their growth in the US.
17. Apian, a Meridian Health Ventures portfolio company, has grown alongside partners like Meridian Health Ventures and Trusts like Guy’s and St Thomas’ NHS Foundation Trust.
18. Partners in the fund are committed to harnessing accelerations in new digital and biomedical advances to deliver better, faster, and fairer healthcare.
19. Guy’s and St Thomas’ NHS Foundation Trust, King’s College Hospital, University College London Hospitals, Cedars-Sinai Medical Center, and Hartford HealthCare are among the backers of the fund.
20. Apian's CEO, Alex Trewby, believes the new transatlantic fund creates a win-win for patients, clinicians, and health tech founders like themselves.
21. Science plays a crucial role in addressing medical-conditions, chronic-diseases like cancer, respiratory-conditions, digestive-health, eye-health, hearing, mental-health, and neurological-disorders.
22. Technological advancements like therapies-and-treatments, nutrition, cardiovascular-health, and artificial-intelligence are critical in improving health and wellness.
23. Fitness-and-exercise, environmental-science, and energy contribute to enhancing general health and wellbeing.
24. Lifestyle factors, such as relationships, pets, travel, cars, education-and-self-development, personal-growth, shopping, career-development, and hobbies like casino-and-gambling, politics, general-news, crime-and-justice, learning, and more impact health significantly.
25. Fashion-and-beauty, food-and-drink, home-and-garden, finance, personal-finance, and banking-and-insurance influence health indirectly, yet have a notable impact.
26. Health-tech, along with gadgets, data-and-cloud-computing, and technology, is a growing industry transforming the way healthcare is delivered.
27. Manufacturing and cybersecurity are essential to the development and protection of healthtech innovations.
28. Skin-conditions, personal-finance, and climate-change are interconnected issues that need attention for a holistic approach to health and well-being.

Read also: